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We studied here the clinical course of heterozygous carriers
of X-linked Alport syndrome and a subgroup of patients with
thin basement membrane disease due to heterozygous
autosomal recessive Alport mutations whose prognosis may
be worse than formerly thought. We analyzed 234 Alport
carriers, including 29 with autosomal recessive mutations.
Using Kaplan–Meier estimates and log-rank tests, autosomal
and X-linked carriers were found to have similar incidences of
renal replacement therapy, proteinuria, and impaired creatinine
clearance. Further, age at onset of renal replacement therapy
did not differ between X-chromosomal and autosomal carriers.
Both groups showed an impaired life expectancy when reaching
renal replacement therapy. RAAS inhibition significantly delayed
the onset of end-stage renal failure. Not only carriers of X-linked
Alport mutations but also heterozygous carriers of autosomal
recessive mutations were found to have an increased risk for
worse renal function. The risk of end-stage renal disease in
both groups affected life expectancy, and this should cause
a greater alertness toward patients presenting with what
has been wrongly termed ‘familial benign hematuria.’ Timely
therapy can help to delay onset of end-stage renal failure.
Thus, yearly follow-up by a nephrologist is advised for X-linked
Alport carriers and patients with thin basement membrane
nephropathy, microalbuminuria, proteinuria, or hypertension.
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Alport syndrome is a hereditary basement membrane
disorder due to mutations within type IV collagen genes.1,2
Mutations of the COL4A5 gene encoding the a5-chain of
type IV collagen lead to X-linked Alport syndrome (XLAS),
whereas mutations of the COL4A4/COL4A3 genes encoding
the a3/a4 (IV) chains cause the autosomal recessive form
(ARAS) of the disease.3,4 Men with XLAS and patients of
both genders with homozygous ARAS mutations represent
the completely developed pattern of the disease with end-
stage renal failure during adolescence or early adulthood,
including hearing loss and ocular lesions in most of them.5 In
these patients, the course of Alport syndrome has been well
studied, including their genotype–phenotype correlations5–7
and the beneficial effect of timely nephroprotective therapy.8
Analysis of heterozygous XLAS carriers in the ‘European
Community Alport Syndrome Concerted Action’9 showed a
large variability of the clinical course. Hematuria was found
in 96% and proteinuria in 75% of the patients; 18% reached
end-stage renal failure (59% of them before the age of 40
years). These data showed that the diagnosis of heterozygous
COL4A5 mutations is not equivalent to a benign course of
disease. The reasons for the large inter- and intrafamilial
variability in clinical manifestations in those female patients
are only partially known; probably X-inactivation has a
pivotal role.10
Heterozygous COL4A3/COL4A4 mutations result in the
phenotype ‘familial benign hematuria’ or ‘thin basement
membrane nephropathy’ (TBMN).11–13 Affected subjects
typically present with hematuria. Histologically, TBMN is
characterized by a uniformly thinned glomerular basement
membrane. Having been regarded as ‘benign’ familial
hematuria for a long time, these patients might have an
increased risk to develop severe renal impairment14–19—
comparable to the findings in female XLAS carriers (see
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above). TBMN is not a rare disease, as at least 1% of the
population is affected;12,18 in a series of 76 renal transplant
biopsies, even 5.2% of the kidneys presented a thinned
glomerular basement membrane.16
For the first time, the present study compares the risk of
renal impairment, end-stage renal disease, and premature
death between heterozygous carriers of XLAS and ARAS
mutations. In addition, the nephroprotective effect of
renin–angiotensin–aldosterone system (RAAS) blockade in
patients with heterozygous Alport mutations is evaluated.
RESULTS
Founded in 2006, the European Alport Registry retraces
clinical and therapeutic data on several decades in three
generations of Alport families across Europe. Patient
information, study protocol, questionnaire (see Supplemen-
tary Material online), consent form (in English, French,
Spanish, and German), data collection, anonymization, and
storage conform with good clinical practice guidelines, and
were approved by the Ethics Committee (AZ 10/11/06;
authorization of French data by the Commission Nationale
de l’Informatique et des Liberte´s #908249).
Heterozygous ALAS and XLAS mutations both can lead to
impaired renal function and end-stage renal disease
Analysis included 234 patients, 29 of them with ARAS
mutations (14 men and 15 women); the mean age of all
patients was 35.1±19.5 years, and the mean age at start of
RAAS blockade therapy was 28.2±15.7 years. In all, 3 (10.3%)
of these ARAS patients are currently under renal replacement
therapy, 5 (17.2%; mean age 45 years) show an impaired
creatinine clearance, 10 (34.5%; mean age 35 years) present with
proteinuria, and 10 (34.5%; mean age 15 years) with
microalbuminuria. In all, 189 patients had a XLAS mode of
inheritance (16 patients with unknown mode, but biopsy-
proven thin basement membrane disease). Of them, 29 (15.4%)
are under renal replacement therapy, 27 (14.3%; mean age 48
years) have an impaired creatinine clearance, 63 (33.0%; mean
age 29 years) present with proteinuria, and 35 (18.5%; mean age
24 years) with microalbuminuria (Figure 1 and Table 1).
Heterozygous ARAS and XLAS mutations both can lead to
renal replacement therapy late in life
A total of 41 patients (34 XLAS carriers) reached end-stage
renal failure (median age at onset of renal replacement
therapy (RRT) 49 years, 95% confidence interval (CI) 59–75
years; 1 male, 40 females; Figure 2). Of them, 6 had a
nephroprotective RAAS blockade before start of RRT; 11
received a kidney transplant, and 3 of these kidney transplants
failed (after 16, 15, and 7.5 years). There are no significant
differences in age at onset of RRT between the groups.
Progressive renal failure might affect life expectancy in
heterozygous carriers
Life expectancy was evaluated in 213 carriers; 21 of these
patients were on RRT (transplanted or dialysis). A total of
seven patients died (two transplanted patients, four under
dialysis, and one under dialysis, who had undergone
transplantation earlier). As this is a relatively small number
of events, the median time of survival could not be
determined. Therefore, survival is described by the 75%
quartile, which is calculated to be 70 (95% CI 67–undeter-
mined years). ‘Time on dialysis’ was found to affect life
expectancy; therefore, end-stage renal disease in Alport
carriers seems to increase the risk of premature death
(Figure 3; Supplementary Materials S1 and S2 online).
RAAS blockade delays renal failure in heterozygous Alport
carriers
A total of 111 patients (47%) received nephroprotective
therapy (mean age at onset of therapy 28 years): 109 were
treated with angiotensin converting enzyme inhibitors
(ACEis), 34 with angiotensin receptor blockers, and 21 with
a combination of ACEis and angiotensin receptor blockers
(Figures 4 and 5). The number of ARAS heterozygotes on
therapy was too low for separate analysis in Figure 4. Average
time on therapy was 5.8 years (s.d.¼ 3.8 years, range 1–21
years). Among the patients under therapy, 53 (47.4%)
currently have proteinuria, 27 (24.3%) have an impaired
creatinine clearance, and 17 (15.3%) have microalbuminuria.
Six patients (5.4%) patients reached end-stage renal failure
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Figure 1 |Prevalence of renal replacement therapy (RRT),
impaired creatinine clearance (Imp. clear.), proteinuria, and
microalbuminuria (Microalb.) in heterozygous autosomal
recessive form and X-linked Alport syndrome carriers do not
differ significantly.
Table 1 | Renal impairment in heterozygous ARAS and XLAS
carriers: total numbers, proportions, and mean ages
Autosomal recessive X-linked
Renal replacement therapy 3/29 (10.3%) 29/188 (15.4%)
Impaired creatinine clearance 5/29 (17.2%; 44.8
years)
28/188 (14.9%; 48.2
years)
Proteinuria 10/29 (34.5%; 34.7
years)
62/188 (33.0%; 28.5
years)
Microalbuminuria 10/29 (34.5%; 15.4
years)
35/188 (18.6%; 24.3
years)
Abbreviations: ARAS, autosomal recessive form; XLAS, X-linked Alport syndrome.
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despite RAAS blockade. In contrast, 124 patients did not
receive any nephroprotective therapy, 7 of them (5.7%)
showed an impaired creatinine clearance, 20 (18.0%) had
proteinuria and 37 (33.3%) had microalbuminuria; 28
untreated subjects (25.2%) reached end-stage renal failure
(Figure 4).
Age at onset of RRT in patients having received a
nephroprotective therapy before end-stage renal failure differs
from untreated patients: onset of RRT occurred significantly
later in carriers who were treated with RAAS blockade
(Figure 5; Po0.0001). Whether this association is causal
requires further study. Subgroup analysis revealed a significant
effect of RAAS blockade in delaying onset of RRT in XLAS
carriers (Po0.0001), as well as in ARAS heterozygotes
(P¼ 0.0231; log-rank test, Supplementary Material S1 online).
DISCUSSION
The aim of the study was to show potential differences in the
clinical course of renal damage in heterozygous carriers with
either XLAS or ARAS mutations. Further, for the first time,
the study investigates the possible impact of a nephropro-
tective RAAS inhibition in this population.
Our study is in agreement with previous findings in 288
female XLAS carriers with a widespread range of disease
severity. The risk of end-stage renal disease was about 30% at
the age of 60 years; chronic renal failure appeared in 12%.9
Forty years before, Gaboardi and co-workers described
similar results in 19 Alport families.20 Similar to previous
investigations,9 our study might as well overestimate the risk
of end-stage renal disease in XLAS carriers (as our
questionnaires asked for other affected family members).
Possible additional risk factors such as hypertension,
nephrotoxic medication, or kidney donation21 might have
an important role in aggravation of renal disease. Further
studies in animal models for TBMN should focus on
these risk factors in order to find new nephroprotective
strategies.22
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Figure 2 |Age at onset of renal replacement therapy in
carriers with either X-linked Alport syndrome or autosomal
recessive form mutations does not differ significantly.
Kaplan–Meier estimate.
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Figure 3 |Progressive renal failure leading to end-stage renal
disease can affect life expectancy in heterozygous carriers of
Alport mutations. Kaplan–Meier estimate for all carriers including
those on renal replacement therapy (n¼ 21) and for the female
population in Germany in 2008 (black, Human Mortality Database,
University of California, Berkeley, CA, and Max Planck Institute for
Demographic Research (Germany)). Available at http://
www.mortality.org or http://www.humanmortality.de (data
downloaded on 31 August 2011).
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Figure 4 |Prevalence of renal replacement therapy (RRT),
impaired creatinine clearance (Imp. clear.), proteinuria, and
microalbuminuria (Microalb.) in patients with and without
renin–angiotensin–aldosterone system blockade.
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Figure 5 |Onset of renal replacement therapy is significantly
delayed in carriers with preemptive nephroprotective therapy
before end-stage renal failure (Po0.0001). Kaplan–Meier
estimate.
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Although the increased risk for renal failure in XLAS
carriers is well established,9,23 the prognosis of TBMN due to
heterozygous ARAS mutations might be worse than formerly
supposed. In our study, ARAS and XLAS carriers show no
significant differences in the incidences of RRT, proteinuria,
and impaired creatinine clearance (Figures 1 and 2).
Microalbuminuria was even more common in ARAS than
in XLAS carriers. Age differences between both groups were
excluded as a potential confounder (as older patients show a
higher incidence of renal damage caused by other reasons
such as diabetes, hypertension, atherosclerosis, etc.). ARAS
carriers had an even lower mean age than patients with
X-linked disease (Table 1).
Our study design and our questionnaires might have
overestimated the risk of end-stage renal disease in TBMN.
Patients who have not been recognized as heterozygous
carriers were not included in any analysis. However, every
single patient with end-stage renal failure due to TBMN still
presents a very significant finding, as this is in contrast to the
synonym of TBMN: ‘familial benign hematuria’. Further, the
high prevalence of 1:100 makes TBMN a major source of
chronic renal disease in the general population.11,12,16–19
RAAS blockade significantly delays the onset of end-stage
renal failure in proteinuric Alport carriers who received
therapy before onset of RRT (Figure 5). This beneficial effect
is not caused by a selection bias toward ‘better’ patients in the
treatment group: the number of patients with proteinuria
and impaired renal function is even higher in the therapy
group (as both medical conditions increase the likelihood of
starting therapy; Figure 4). Because of the low numbers of
ARAS heterozygotes on therapy, our study could not analyze
XLAS and ARAS groups separately in Figure 4. For that
reason, our results (mostly on heterozygous XLAS) should
not be generalized for all ARAS heterozygotes. Further
genotype–phenotype analyses in ARAS mutations would be
of great use to preemptively provide patients with therapeutic
options. However, one can expect a large number of patients
with TBMN to remain undiscovered, because their ongoing
renal disease is unrecognized (or otherwise explained by
‘unknown disease’, hypertension, atherosclerosis, or analge-
tica abuse). Within the next few years, the use of genetic
mutation screening will become more common. Thus,
TMBN patients can be easily identified, which poses the
possibility to start nephroprotective therapy earlier. Accord-
ing to our study, widespread preemptive RAAS blockade in
TBMN patients with microalbuminuria, proteinuria, or high
blood pressure could prevent a large number of severe
impairments of renal function and even dialysis.
Heterozygous carriers of XLAS and ARAS mutations both
show an impaired life expectancy when reaching RRT.
Preventive RAAS blockade might prolong life and improve
quality of life in these carriers. The relatively high risk of end-
stage renal disease and the impaired life expectancy of Alport
carriers on RRT should lead to a greater alertness toward
patients with TBMN presenting the non-benign symptoms of
familial benign hematuria. The term ‘familial benign
hematuria’ is misleading and has an underlying renal disease
that can affect quality of life and life expectancy. As these
patients reflect 1% of the total population, the sometimes
non-benign course of TBMN and XLAS carriers is relevant to
nephrologists. Yearly follow-up by a nephrologist and early-
on nephroprotective RAAS blockade should be advised for all
newly diagnosed TBMN patients with microalbuminuria,
proteinuria, or high blood pressure, and heterozygous XLAS
carriers.
MATERIALS AND METHODS
Inclusion and exclusion criteria
The diagnosis of the heterozygous status was proven by (1)
mutation analysis or (2) kidney biopsy plus genetic consultation
for decision in between XLAS or ARAS inheritance (including a
conclusive genealogic tree and/or linkage analysis). Patients were
excluded if they were affected males with XLAS or patients with
genetically proven homozygous ARAS. Patients were excluded if
they did not give informed consent or the diagnosis was suspected
but not confirmed or if they donated a kidney (living donor to
affected family member).
Primary data collection, assignment, and follow-up
The Registry retraces data on several decades in three generations of
Alport syndrome patients, hindering a prospective study design. In
all, 310 centers participated in the European Alport Registry over the
years. Data were hosted centrally on a non-open access computer
and were anonymized at the University of Go¨ttingen, Germany.
Questionnaires included demographic data (age, gender, country of
origin, family history, mode of inheritance), clinical and laboratory
data (how the diagnosis was made, age at onset of RRT, ACEi therapy,
and age at onset of therapy, renal parameters before and after onset of
ACEi therapy such as proteinuria, creatinine, creatinine clearance,
cholesterol, hypertension, hearing loss, eye symptoms, death from
all causes, and side effects of medications such as hyperkalemia,
angioedema, renal failure, cough, hypotension, rhabdomyolysis,
and others). Data were updated via telephone interviews, email,
facsimile, or by personal contact with both physicians and patients.
The registry and data storage conform with good clinical practice
guidelines, and were approved by the Ethics Committee (AZ 10/11/
06; French data by the Commission Nationale de l’Informatique
et des Liberte´s #908249). Data were collected from Germany, France,
Spain, Belgium, Austria, Switzerland, United States of America
(limited to only those families recently moved from Europe to
USA), Russia, Serbia, Romania, Italy, and Turkey. The primary data
set was updated exclusively in spring 2010 by the lead investigator to
ensure compliance to the Ethics Committee recommendations. Data
were updated within 12 months of the analysis date in 86% of cases.
Of 393 (2%) patients or carriers, 8 were lost to follow-up.
Outcome measures and intervention
The study end points were ‘RRT’, ‘age at onset of RRT’, ‘impaired
renal function’ (creatinine-clearance below 60 ml/min), ‘proteinuria’
(proteinuria 4300 mg/day), and ‘age at death’. Owing to the genetic
defect in Alport carriers at birth, life expectancy was defined as life
span from birth to death. Impaired creatinine clearance was defined
aso60 ml/min in a 24-h urine collection. Proteinuria was defined as
4300 mg protein per day, and microalbuminuria as 30–300 mg
protein per day in a 24-h urine collection. The study explored the
treatment effects of ACEis and angiotensin receptor blockers; the
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control intervention was with out therapy. The most commonly
used ACEis were Ramipril (0.025–0.1 mg/kg body weight) and
Enalapril (0.125–1.0 mg/kg body weight).
Statistical analysis
Distributions of continuous variables are summarized by means,
whereas frequencies and percentages are given for categorical
(including binary) variables. The efficacy end points ‘age at onset
of RRT’ and ‘age at death’ are censored in some patients, as not all
patients included in the analyses have started RRT (or died).
Therefore, appropriate statistical methods for censored time-to-
event data were used, including the Kaplan–Meier estimator and the
log-rank test.24 Median event times are reported with 95% CIs,
which are based on log–log transformed CIs of the event
probabilities. If the CIs of the event probabilities are too wide
across all observed times because of the small sample size, the
confidence limits for the median cannot be determined. All analyses
are of an exploratory nature and therefore no correction for multiple
testing was applied. All reported P-values are two-sided, and those
smaller than 0.05 are referred to as statistically significant. All
inferential analyses were carried out using SAS version 9.2.
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